KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Return on Sales (2017 - 2025)

Aquestive Therapeutics has reported Return on Sales over the past 9 years, most recently at 2.45% for Q4 2025.

  • Quarterly results put Return on Sales at 2.45% for Q4 2025, down 101.0% from a year ago — trailing twelve months through Dec 2025 was 1.88% (down 111.0% YoY), and the annual figure for FY2025 was 1.88%, down 111.0%.
  • Return on Sales for Q4 2025 was 2.45% at Aquestive Therapeutics, down from 1.21% in the prior quarter.
  • Over the last five years, Return on Sales for AQST hit a ceiling of 0.72% in Q1 2023 and a floor of 6.18% in Q2 2021.
  • Median Return on Sales over the past 5 years was 1.13% (2022), compared with a mean of 1.44%.
  • Biggest five-year swings in Return on Sales: surged 415bps in 2022 and later plummeted -179bps in 2024.
  • Aquestive Therapeutics' Return on Sales stood at 2.61% in 2021, then surged by 56bps to 1.16% in 2022, then surged by 47bps to 0.61% in 2023, then tumbled by -134bps to 1.44% in 2024, then crashed by -70bps to 2.45% in 2025.
  • The last three reported values for Return on Sales were 2.45% (Q4 2025), 1.21% (Q3 2025), and 1.35% (Q2 2025) per Business Quant data.